先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02096 先声药业

未开盘 09-08 16:08:36

11.630

+0.050

+0.43%

最高11.760	最低11.460	成交量211.10万
今开11.600	昨收11.580	日振幅2.59%
总市值298.66亿	流通市值298.66亿	总股本25.68亿
成交额2,447万	换手率0.08%	流通股本25.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02096","market":"HK","secType":"STK","nameCN":"先声药业","latestPrice":11.63,"timestamp":1788854916002,"preClose":11.58,"halted":0,"volume":2111000,"delay":0,"changeRate":0.004317789291882618,"floatShares":2568000000,"shares":2568000000,"eps":0.6313027318633755,"marketStatus":"未开盘","change":0.05,"latestTime":"09-08 16:08:36","open":11.6,"high":11.76,"low":11.46,"amount":24472315,"amplitude":0.025907,"askPrice":11.64,"askSize":8000,"bidPrice":11.63,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":0.711723685427971,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":0,"adr":0,"listingDate":1603728000000,"exchange":"SEHK","adjPreClose":11.58,"dividendRate":0.018088,"openAndCloseTimeList":[[1788831000000,1788840000000],[1788843600000,1788854400000]],"volumeRatio":0.295253,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02096","defaultTab":"news","newsList":[{"id":"2664895633","title":"首款国产长效RSV预防单抗获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664895633","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664895633?lang=zh_cn&edition=full","pubTime":"2026-09-04 12:58","pubTimestamp":1788497911,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","IPOS","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664238859","title":"【券商聚焦】交银国际：医药行业收入稳健增长 多重利好推动盈利表现显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2664238859","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664238859?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:00","pubTimestamp":1788483634,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，1H26港股/A股医药行业整体收入增长4.7%/3.2%。创新药产业链增速领跑行业，服务板块复苏：1）港股/A股CXO收入整体增长29.2%/25.3%，（扣非）净利润增长23.4%/67.6%，在各子板块中增速最快，行业整体景气度和订单需求处于高位。2）核心成药板块收入增长17.8%/3.4%、利润增长62.7%/35.0%。其中生物药增速远超化药，在板块收入中的占比也进一步提升。3）医院、器械、诊断、疫苗等板块业绩有复苏趋势。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","IE00B0JY6N72.USD","01951","KURE","09926","LU0315179316.USD","01276","LU0039217434.USD","03329","06160","02269","03759","LU1242518857.USD","HK0000320264.USD","01952","HK0000306685.HKD","02162","LU0327786744.USD","02268","BK1161","BK1589","01530","02596","BK1515","01093","06821","IE00B543WZ88.USD","LU0588546209.SGD","09966","BK1209","SG9999004220.SGD","06990","03692","LU0307460666.USD","02096","LU1251922891.USD","06996","KCE","LU2543165471.USD","LU1880383366.USD","LU0348783233.USD","IE00B5MMRT66.SGD","01177","06078","02273","LU1152091168.USD","LU0856984785.SGD","09996","01548","00013"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664280009","title":"先声药业：英沐乐获药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664280009","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664280009?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:51","pubTimestamp":1788483060,"startTime":"0","endTime":"0","summary":"9月3日，先声药业（02096）发布公告，宣布其与瑞阳（山东）生物制药有限公司的战略合作项目，国产1类生物新药库莱韦拜单抗（商品名：英沐乐?）已获得中国国家药品监督管理局批准上市。该药物用于即将进入或出生在第一呼吸道合胞病毒（RSV）流行季的胎龄≥35周的新生儿和婴儿，预防RSV引起的下呼吸道感染，特定排除患有慢性肺疾病的儿童。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609043864735568.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609043864735568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02096","IPOS","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664687715","title":"先声药业(02096.HK)：英沐乐®获国家药品监督管理局批准在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2664687715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664687715?lang=zh_cn&edition=full","pubTime":"2026-09-03 21:32","pubTimestamp":1788442378,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120495764","title":"先声药业9月2日回购105.30万股股份，约耗资1,235.74万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120495764","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120495764?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:52","pubTimestamp":1788353554,"startTime":"0","endTime":"0","summary":"先声药业（02096）于2026年9月2日发布翌日披露报表，公司于当日在香港联交所场内回购普通股共计1,053,000股，占回购前已发行股本约0.041%。回购价格区间介乎每股11.4711港元至11.86港元，合计支付对价约12,357,390港元，折合约1,235.74万港元。\n本次回购后，先声药业的已发行股本保持在2,568,198,618股，库藏股数量为0。公司于2026年6月12日曾通过购回授权，本次回购系在相关授权下进行，公司最多可购回256,819,861股。先声药业在公告中确认已遵守香港联交所证券上市规则及相关法律法规。\n本公告由先声药业联席公司秘书朱达签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"先声药业9月2日回购105.30万股股份，约耗资1,235.74万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664143938","title":"先声药业(02096)9月2日耗资约1235.74万港元回报105.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664143938","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664143938?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:45","pubTimestamp":1788353149,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)公布，2026年9月2日耗资约1235.74万港元回报105.3万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02096","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133114746","title":"先声药业8月无新增发行或库存股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1133114746","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133114746?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:23","pubTimestamp":1788348232,"startTime":"0","endTime":"0","summary":"先声药业于2026年9月2日发布月报表，披露公司截至2026年8月31日止期间股本和股份变动情况。公告显示，先声药业在该月未发生新增股份发行或回购、注销及库藏股等活动。先声药业目前的已发行股份数量为2,568,198,618股，较上月底持平。此外，根据公告，公司确认其公众持股比例符合15.45%的最低要求。公告还披露，于2023年6月15日通过修订的受限制股份单位计划已预留235,201,361股作为潜在发行额度。本月内暂未实际新发行股份或转让库存股份。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664890854","title":"先声药业“牵手”罗氏 三特异抗体SIM0660达成全球开发合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890854","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664890854?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:50","pubTimestamp":1788339000,"startTime":"0","endTime":"0","summary":"9月1日晚间，先声药业集团有限公司（以下简称“先声药业”）公告称，已与罗氏（Roche）就CD79a/CD19/CD3三特异性抗体SIM0660达成全球开发和商业化合作。根据协议条款，罗氏将获得SIM0660在全球范围内的独家开发、生产与商业化权益。先声药业将有资格收取最高可达15.30亿美元的总交易付款，其中包括7500万美元首付款。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862813481.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862813481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664789936","title":"港股异动 | 先声药业(02096.HK)午后涨近6% 罗氏15.3亿美元拿下先声再明SIM0660全球权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664789936","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664789936?lang=zh_cn&edition=full","pubTime":"2026-09-02 14:07","pubTimestamp":1788329268,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664718860","title":"先声药业（02096）涨超3% 与罗氏签署独家授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664718860","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664718860?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:46","pubTimestamp":1788313584,"startTime":"0","endTime":"0","summary":"金吾财讯 | 先声药业（02096）早盘股价反复向上，最新报11.37港元，涨3.46%，成交额3552.39万港元。公司旗下抗肿瘤创新药公司先声再明宣布，已与罗氏（Roche）签署独家授权许可协议，就先声再明对多种B细胞相关疾病具有治疗潜力的CD79a/CD19/CD3三特异性抗体SIM0660达成全球开发和商业化合作。根据协议条款，罗氏将获得SIM0660在全球范围内的独家开发、生产与商业化权益。先声再明将有资格收取最高可达15.30亿美元的总交易付款，其中包括7500万美元首付款。基于未来净销售额，先声再明亦可能有权收取最高至双位数的分级特许权使用费。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990348","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664940860","title":"港股开盘 | 恒指低开0.19% 医药股走强、黄金股普跌 先声药业(02096)涨近5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664940860","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664940860?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:36","pubTimestamp":1788313008,"startTime":"0","endTime":"0","summary":"9月2日，恒生指数低开0.19%，报25,280.82点；恒生科技指数跌0.41%，报4,532.22点。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260902/20260902093453_16718.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260902/20260902093453_16718.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02096","BK1583","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664529860","title":"港股早盘偏软 恒指低开0.19% 洛阳钼业（03993）跌3.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664529860","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664529860?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:26","pubTimestamp":1788312365,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘偏软，恒指低开0.19%，国企指数低开0.18%，恒生科技指数低开0.41%。先声药业高开4.82%，公司宣布，于2026年9月1日，集团与F.Hoffmann-LaRocheLtd签署独家授权许可协议）。根据该协议条款，罗氏将获得SIM0660的全球范围内独家开发、生产与商业化权益。港股表现受压，加息预期再度升温，不利大市气氛，指数低开后持续向下，低见25,200点水平，其后跌幅稍为收窄，整体成交保持清淡。蓝筹股普遍下跌，科网股及内房股持续弱势，资金则流入内银股避险。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990339","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1528","600938","LU1807302812.USD","LU2351347302.SGD","LU0128522157.USD","03419","LU2097828631.EUR","HK0000286598.CNH","LU1634259391.SGD","LU1251922891.USD","BK1227","LU0228367735.SGD","LU0293314216.USD","LU1568876251.USD","LU0708995583.HKD","LU0501845795.SGD","LU0633140727.USD","LU0266512473.USD","LU1064131003.USD","80883","LU0737861699.HKD","LU1504937902.USD","IE0034224299.USD","LU1303224171.USD","LU1064130708.USD","LU0106959298.USD","BK1515","IE00BYV24P56.USD","HK0000320264.USD","HK0000107257.USD","LU0039217434.USD","LU1719994722.HKD","LU2008162690.USD","BK1610","LU1831875114.USD","LU0561508036.HKD","LU1497734951.SGD","LU0359202008.SGD","07500","KURE","CICHY","LU1044876610.USD","00883","LU0791591158.USD","02096","LU1951186391.HKD","07200","LU0096374516.USD","LU0979878070.USD","IE00B031HY20.USD","LU0067412154.USD","LU0516422952.EUR","LU0828238088.HKD","LU0287142896.SGD","LU0823039010.USD","LU0572944931.SGD","IE0032431581.USD","BK1505","LU1497733631.SGD","LU0047713382.USD","LU1224444064.USD","02833","BK1582","LU0828237510.HKD","LU0469268626.HKD","LU0048580855.USD","BK1592","BK1580","LU2213484517.USD","03143","83115","LU2242644610.SGD","LU0630378429.USD","LU1366334578.USD","LU1224709979.USD","LU2187417386.USD","LU2148510915.USD","513600","LU1769817096.USD","SG9999014674.SGD","LU0049853897.USD","LU0819121731.USD","LU0348766576.USD","LU0856984785.SGD","LU0315179316.USD","LU1211504680.USD","LU2097828805.USD","LU0264606111.USD","LU1785774172.SGD","03115","LU0329678337.USD","LU2097828557.USD","HSTECH","LU0320764599.SGD","LU2097828714.EUR","09973","LU0348767384.USD","09115","01519","LU0540923850.HKD","LU0918141705.HKD","LU0572940350.SGD","SG9999001051.SGD","LU0862451837.USD","SG9999007991.SGD","LU1242518931.SGD","BK1544","LU0061477393.USD","IE00BPRC5H50.USD","HK0001040168.HKD","LU1880383440.USD","LU0228659784.USD","LU0516422366.SGD","LU0149721374.USD","601899","TCHI","LU0259732245.USD","LU0417516738.SGD","09633","BK1198","HK0000288743.USD","LU0823040885.USD","LU0611395673.USD","LU1497733557.USD","BK1594","LU0328353924.USD","06181","LU0823038988.USD","LU1522347837.USD","BK1521","LU0737861772.HKD","LU1188198961.HKD","LU1048596156.SGD","MCHmain","LU0231483743.USD","LU0828237940.HKD","LU0972618739.USD","LU0029875118.USD","IE00B5MMRT66.SGD","LU0181495838.USD","LU1769817179.HKD","00992","LU0211977185.USD","BK1560","BK1583","BK1191","LU0633140560.USD","LU0128525689.USD","LU1023057109.AUD","LU0348805143.USD","LU2226246903.HKD","LU3063872942.SGD","IE00BZ08YT58.USD","LU0516423174.USD","LU0165289439.USD","LU0871576103.HKD","LU2264538146.SGD","LNVGY","LU0164865239.USD","LU0865486749.SGD","LU0821914370.USD","SG9999002828.SGD","LU0868486357.SGD","LU0314109678.HKD","BK1540","LU1961090484.USD","LU1226288170.HKD","BK1238","LU0329678170.USD","601939","LU0082770016.USD","LU0244354667.USD","LU0320764755.SGD","LU0499858602.USD","LU1770034418.SGD","LU2087589342.USD","LU0269904917.USD","LU0106252389.USD","LU1481107354.HKD","ZIJMY","LU0886674414.USD","02800","LU1235295612.USD","LU1242518857.USD","LU0762540952.USD","LU1880383366.USD","LU0345776255.USD","HK0000320223.HKD","BK1607","LU0082770016.SGD","LU0348735423.USD","LU1046422090.SGD","LU2039709279.SGD","LU2929501877.USD","LU0359201612.USD","LU0588545904.SGD","LU0348814723.USD","LU0348825331.USD","IE00BZ08YS42.EUR","LU1770036033.HKD","IE00B19Z5X02.USD","LU0890818403.SGD","LU0819123356.HKD","SG9999002562.SGD","LU0463099449.HKD","LU0791590937.USD","NNFSF","HHImain","HK0000288784.HKD","LU0683595622.HKD","LU0140636845.USD","SGXZ90724238.SGD","IE00BGHQDM52.EUR","LU0509642566.USD","LU0326950275.SGD","LU0052756011.USD","LU1988902786.USD","IE00B0JY6N72.USD","LU0348816934.USD","LU1226288253.USD","BK1151","LU0431992006.USD","BK1119","603993","LU1960683339.HKD","BK1231","IE00BMCWC346.EUR","LU1813983027.USD","LU0164939612.USD","LU1044874839.SGD","LU0072913022.USD","LU1226287792.SGD","LU1642822792.SGD","SG9999004220.SGD","LU1794554557.SGD","LU0634319403.HKD","IE00BVYPNQ40.USD","LU1282651121.HKD","LU0396098781.USD","LU0797268264.HKD","BK1149","LU1267930227.SGD","LU0052750758.USD","BK1190","LU1282651048.USD","LU1808992512.USD","80992","LU0516422440.USD","LU0084288322.USD","SG9999002463.SGD","IE00B543WZ88.USD","00939","LU1720050803.USD","LU0516423091.SGD","LU1152091754.HKD","LU1568876335.HKD","HK0000165453.HKD","IE00BWDBJ730.SGD","IE00BZ08YR35.GBP","LU1064131342.USD","LU1328277881.USD","IE0008369823.USD","BK1589","LU0274383008.USD","SG9999009443.AUD","LU0345780281.USD","LU1981816686.USD","SG9999013353.USD","LU0588545730.USD","LU0345775950.USD","BK1526","HSI","LU0417516902.SGD","LU0918141887.USD","LU0345780521.USD","03037","LU1105468828.SGD","LU2177674079.SGD","03993","LU0266512127.USD","LU1152091168.USD","LU1226287875.USD","SG9999004311.SGD","LU0441854154.USD","LU0043850808.USD","LU1044875133.USD","BK1167","HK0000306701.USD","IE0003895053.USD","02899","LU1993786604.SGD","07300","LU2097828474.EUR","LU0359201885.HKD","LU0499858438.USD","LU0315178854.USD","BK1504","LU0880133367.SGD","LU1366334651.USD","LU1282648689.USD","IE00BVYPNP33.GBP","LU0307460666.USD","LU0543330483.HKD","00285","LU0173614495.USD","LU0049112450.USD","LU0456854461.SGD","HK0001040143.USD","LU0572939691.SGD","LU1008478684.HKD","BK1193","LU0163747925.USD","IE00BQJZWZ67.USD","01093","LU0620787316.HKD","LU0588546209.SGD","LU0370786039.SGD","LU1323998911.USD","LU0327786744.USD","LU1226287529.USD","HK0000306685.HKD","LU0310800965.SGD","IE00B3M56506.USD","LU1634259557.SGD","LU0672654166.SGD","LU0164880469.USD","LU0831093199.SGD","LU2399975544.HKD","IE0008368742.USD","LU1048484197.HKD","LU0862451753.SGD","BK1200","LU0348827113.USD","82800","LU0675040207.SGD","LU0588545490.SGD","LU0531971595.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664605198","title":"港股异动 | 先声药业(02096.HK)高开近5% 与罗氏就三特异抗体SIM0660达成15.3亿美元授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664605198","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664605198?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:24","pubTimestamp":1788312284,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146496068","title":"先声药业（02096）与罗氏签订SIM0660全球独家授权协议：首付款7,500万美元，里程碑付款最高14.55亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146496068","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146496068?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:06","pubTimestamp":1788257190,"startTime":"0","endTime":"0","summary":"2026年9月1日，先声药业公告称，其与F. Hoffmann-La Roche Ltd（罗氏）签署独家授权许可协议。根据协议，罗氏将获得SIM0660在全球范围内的开发、生产及商业化独家权利。先声药业将获得7,500万美元首付款，并有权在未来取得最高14.55亿美元的里程碑付款，另可按未来净销售额收取最高至双位数的分级特许权使用费。先声药业表示，本次授权系其肿瘤T细胞衔接器技术平台第二个实现授权的资产，进一步验证了公司在多特异性抗体研发领域的技术实力及全球化竞争力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664830740","title":"先声药业(02096)与罗氏就SIM0660订立独家授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664830740","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664830740?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:03","pubTimestamp":1788257003,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业 发布公告，于2026年9月1日，本集团与F. Hoffmann-La Roche Ltd(罗氏)签署独家授权许可协议(该协议)。根据该协议条款，罗氏将获得SIM0660的全球范围内的独家开发、生产与商业化权益。SIM0660是一款三特异性抗体，由先声再明的TCE多特异性抗体技术平台开发。此外，SIM0660对B细胞介导的自身免疫疾病也具有治疗潜力，有望通过靶向清除致病性B细胞，为患者带来临床获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"先声药业(02096)与罗氏就SIM0660订立独家授权许可协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02096","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663027666","title":"【高端访谈】“自主研发+协同创新”双轮驱动 公司迈入新发展阶段—访先声药业周云曙","url":"https://stock-news.laohu8.com/highlight/detail?id=2663027666","media":"新华财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663027666?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:19","pubTimestamp":1788157149,"startTime":"0","endTime":"0","summary":"新华财经南京8月31日电（记者朱程）2026年上半年，先声药业交出了一份亮眼成绩单：总营收45.8亿元，同比增长27.8%；经调整净利润9.6亿元，同比增长48.7%；创新药收入占比攀升至85%。这份业绩如何取得？先声药业的国际化布局有哪些新部署？AI制药未来会如何改变行业？近日，记者带着这些问题专访了先声药业集团总裁周云曙。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860023942.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860023942.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","LU0405327148.USD","LU1820825898.SGD","LU2097828474.EUR","LU1255011170.USD","BK1191","LU1064131003.USD","LU1781817850.SGD","LU1328615791.USD","BK0239","LU0405327494.USD","LU1997245094.SGD","LU2148510915.USD","LU1146622755.USD","LU2097828557.USD","LU2097828805.USD","BK1583","LU2097828631.EUR","LU1064130708.USD","BK0188","LU2328871848.SGD","LU2097828714.EUR","LU2488822045.USD","LU2495084118.USD","LU1655091616.SGD","LU2580892789.USD","BK0196","600276","LU2289578879.USD","BK0028","LU2580892862.HKD","02096","BK0012","LU1969619763.USD","LU1997245177.USD","LU1997244956.HKD","LU1580142542.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662207163","title":"【券商聚焦】交银国际维持先声药业（02096）买入评级 指新品集中上市及全球化提速支撑估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2662207163","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662207163?lang=zh_cn&edition=full","pubTime":"2026-08-25 09:23","pubTimestamp":1787620993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，先声药业 1H26收入和经调整净利润分别增长27.8%/48.7%，其中创新药收入+34%至39亿元，对总收入的贡献升至85%。3）自免线艾得辛虽未中标集采，但公司目标维持约50%市场份额。IL-4R和外用JAK1/JAK2凝胶预计2027 年商业化，缓解艾得辛竞争压力。公司维持全年收入100亿元的指引，经调整净利润指引从16亿上调至18亿元。该机构将DCF模型向前滚动至2027 年，得到最新目标价20港元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989224","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02096","REVS","KCE","NIFE","CZA","LCO","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262953","title":"先声药业(02096.HK)根据2021年受限制股份单位计划授出合共79.5万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262953","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661262953?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:51","pubTimestamp":1787309471,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1191","02096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661263935","title":"先声药业2026H1收入45.8亿元 创新药收入占比达84.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661263935","media":"新华财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661263935?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:09","pubTimestamp":1787299786,"startTime":"0","endTime":"0","summary":"新华财经南京8月21日电（记者朱程）先声药业集团发布2026年中期业绩报告。2026年前六个月，该公司实现营业收入45.8亿元，同比增长27.8%；归属于公司权益股东的净利润8.3亿元，同比增长37.9%；经调整归母净利润9.6亿元，同比增长48.7%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608213849274343.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608213849274343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02096","BK1583","159992","MEDX","BK1161","IBBQ","BK1574","LNGR","BK1191","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661425678","title":"先声药业2026年上半年净利润同比增长37.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661425678","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661425678?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:00","pubTimestamp":1787277605,"startTime":"0","endTime":"0","summary":"8月20日，先声药业发布2026年中期业绩公告。上半年，公司实现收入45.8亿元，较2025年同期的35.85亿元增长27.8%；创新药业务收入为38.87亿元，占总收入比率为84.9%，较2025年同期增长34.1%；归属于公司权益股东的利润为8.29亿元，较2025年同期增长37.9%；经调整归属于公司权益股东的利润为9.64亿元，较2025年同期增长48.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608213848957189.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608213848957189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02096"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.simcere.com","stockEarnings":[{"period":"1week","weight":0.0582},{"period":"1month","weight":-0.0659},{"period":"3month","weight":0.2071},{"period":"6month","weight":0.0178},{"period":"1year","weight":-0.1594},{"period":"ytd","weight":-0.0078}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":-0.0137},{"period":"3month","weight":0.0373},{"period":"6month","weight":-0.0155},{"period":"1year","weight":-0.0124},{"period":"ytd","weight":-0.0122}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"先声药业集团有限公司是一家从事药品的研发、生产和销售的公司。该公司的主要产品为仿制药，包括用于中枢神经系统疾病的产品必存、用于肿瘤疾病的产品捷百舒和捷佰立、以及用于自身免疫疾病的产品英太青。该公司还从事生产创新药，比如用于肿瘤疾病的恩度。该公司还从事为医疗机构销售的第三方药品提供推广服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.09318},{"month":2,"riseRate":0.666667,"avgChangeRate":0.070754},{"month":3,"riseRate":0.5,"avgChangeRate":-0.014037},{"month":4,"riseRate":0.5,"avgChangeRate":-0.003707},{"month":5,"riseRate":0.666667,"avgChangeRate":0.105952},{"month":6,"riseRate":0.666667,"avgChangeRate":0.032044},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.001102},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.059624},{"month":9,"riseRate":0.5,"avgChangeRate":-0.019045},{"month":10,"riseRate":0.8,"avgChangeRate":0.108743},{"month":11,"riseRate":0.666667,"avgChangeRate":0.044296},{"month":12,"riseRate":0.5,"avgChangeRate":0.000556}],"exchange":"SEHK","name":"先声药业","nameEN":"SIMCERE PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"先声药业,02096,先声药业股票,先声药业股票老虎,先声药业股票老虎国际,先声药业行情,先声药业股票行情,先声药业股价,先声药业股市,先声药业股票价格,先声药业股票交易,先声药业股票购买,先声药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"先声药业(02096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供先声药业(02096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}